Clinical Trials Logo

Filter by:
NCT ID: NCT05306223 Recruiting - Clinical trials for Tuberculosis, Multidrug-Resistant

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

PROSPECT
Start date: May 10, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not including bedaquiline at the end of treatment in participants with pulmonary MDR-TB in China.

NCT ID: NCT05306132 Recruiting - Clinical trials for Advanced Solid Tumor

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.

NCT ID: NCT05306028 Recruiting - Diabete Mellitus Clinical Trials

Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

About 80% of patients with pancreatic adenocarcinoma have aberrant fasting blood glucose at the time of diagnosis. The consistent association between pancreatic cancer and diabetes mellitus has long been recognized and even been termed as "chicken and egg". Many reports have found that pancreatic cancer can result in diabetes, which is called type 3c diabetes. New-onset diabetes is commonly observed in pancreatic cancer patients and has been considered as a potential screening sign. Moreover, diabetes has been found as a predictor of poor outcome in pancreatic cancer. Pancreatic cancer cells have a strong dependence on glucose and they are well-known for their sweet teeth. High glucose is associated with impaired immunologic reaction, intolerability to chemotherapy, radiotherapy and other major treatments, an increased risk of pancreatic surgery. Given the linkage between pancreatic cancer and diabetes or high blood glucose, a clinical trial is needed to validate the effect of metformin and insulin on regulating blood glucose in type 3c diabetes.

NCT ID: NCT05305885 Recruiting - Clinical trials for Leptomeningeal Metastasis

Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis

Start date: August 19, 2022
Phase: N/A
Study type: Interventional

Intrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Owing to the limited number of agents available for intrathecal chemotherapy, it is crucial to find a novel agent with efficacy and safety. In our phase 1 study, intrathecal pemetrexed showed controllable toxicities and potential promising efficacy for refractory leptomeningeal metastases from non-small-cell lung cancer patients. In our further study, intrathecal pemetrexed combined with involved-field radiation therapy was administered as the first-line intrathecal chemotherapy for leptomeningeal metastases from solid tumors. In this study, intrathecal pemetrexed combined with involved-field radiation therapy showed feasibility and controllable adverse events. It has been proved that pemetrexed as a novel intrathecal drug exhibited promising antitumor effects in cerebrospinal fluid. Moreover, the concomitant therapeutic modality is an optimal treatment option for leptomeningeal metastases from solid tumors. Central nervous system radiotherapy is a part of the specific treatment of leptomeningeal metastases. Radiotherapy has been proved to improve neurologic function and control of parenchymal brain metastases in leptomeningeal metastases treatment. Additionally, radiotherapy is revealed to improve the efficacy and attenuate toxicity of intrathecal chemotherapy as a result of normal cerebrospinal fluid reestablishing. However, it is still controversial whether radiotherapy can improve the overall survival. We conduct this study to further demonstrate the efficacy and safety of intrathecal pemetrexed administration for patients with leptomeningeal metastases from solid tumors by multicenter study. Furthermore, the study of effective treatment modality is of great significance. The safety and antitumor activity of intrathecal pemetrexed combined with involved-field radiation therapy and intrathecal pemetrexed alone were also compared to confirm an optimized therapeutic regimen.

NCT ID: NCT05305872 Recruiting - Wilson's Disease Clinical Trials

Gandouling in the Treatment of Wilson's Disease

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.

NCT ID: NCT05305859 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

NCT ID: NCT05305677 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome

NMN
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to understand the effect of Nicotinamide mononucleotide (NMN) on patients with polycystic ovary syndrome.

NCT ID: NCT05305469 Recruiting - Sepsis Clinical Trials

Early Identification and Prognosis Prediction of Sepsis Through Multiomics

EIPPSM
Start date: January 1, 2022
Phase:
Study type: Observational

This study aims to integrate multi-omics data and clinical indicators to reveal pathogen-specific molecular patterns in patients with sepsis and establish prognostic prediction models through multiple machine learning algorithms.

NCT ID: NCT05305092 Recruiting - Breast Cancer Clinical Trials

Assessment of Brain Cognitive Impairment in Breast Cancer

Start date: May 31, 2022
Phase:
Study type: Observational

To explore the cognitive impairment caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients and to find biomarkers with early predictive effect on this cognitive impairment by using multimodal integrated PET/MRI technology combined with psychobehavioral technology.

NCT ID: NCT05304923 Recruiting - Hypoxia Clinical Trials

Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

This study aims to determine whether the use of SOJV could reduce the rate of hypoxia during gastrointestinal endoscopic procedures in deeply sedated patients sedated at high altitude comparing to the supplemental oxygen administration via nasal cannula.